ARCHIVES

In Brief: Cancer Panel To Meet Aug.29; RFP On Impact Of Planning Cancelled As Being “Premature“

This article is from The Cancer Letter archive.

Vol. 06 No. 33 | August 15, 1980

Download PDF Visit The Full Archive

Related Articles

Low Dose DFMO Reduces Colon Adenoma Recurrence

April 25, 2008

$14.7 Million Earmark Of NCI funds Trigger Protest By Advocates, Scientists

October 24, 1996

Sharfstein To Leave FDA

January 7, 2011

Waksal Pleads Guilty To Securities Fraud

October 18, 2002

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

January 7, 2005

Clinical Trials Approved By NCI Last Month Listed

February 22, 2002